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Abstract
The anaphase promoting complex (APC) is the crucial ubiquitin ligase targeting the regulatory
machinery of the cell cycle. Emi1, a major modulator of APC activity, is thought to act
competitively as a pseudosubstrate. We show that the modulation of APC activity is more subtle:
Emi1 inhibits ubiquitylation at both substrate binding and separately at the step of ubiquitin
transfer to APC-bound substrates. The zinc-binding region of Emi1 allows multiple
monoubiquitylation of substrates, but preferentially suppresses the ubiquitin chain elongation by
UBCH10. Furthermore, the C-terminal tail of Emi1 antagonizes chain elongation by Ube2S, via
competitively preventing its binding to APC cullin subunit through electrostatic interaction.
Combinatorially, Emi1 effectively stabilizes APC substrates by suppressing ubiquitin chain
extension. Deubiquitylating enzymes can then convert inhibited substrates to their basal state.
Chain elongation may be a particularly sensitive step for controlling degradation and this study
provides the first kinetic evidence for how it is inhibited.
Introduction
The anaphase promoting complex (APC) is a multisubunits ubiquitin ligase that controls cell
cycle progression through mitosis to G1 phase1. Various key cell cycle regulators are
ubiquitylated by APC, and targeted for destruction by 26S proteasome. The ubiquitylation
reaction consists of two steps: multiple monoubiquitylation on lysine residues of substrate,
and ubiquitin chain assembly via ubiquitin conjugated on the substrate. Human APC
cooperates with two E2 enzymes, UBCH10, which primarily carries out the first step and
Ube2S, which exclusively carried out the second step, to catalyze efficient
polyubiquitylation preferentially via K11 linkages2, 3.
Various studies have shown that APC activity is tightly regulated at several levels4-7. Given
the dynamic features of E2 activity, direct interference with the E2-E3 association, or
inhibition of the ubiquitin transfer to substrates should be an effective way to inhibit the
ongoing ubiquitylation. Additionally, because degradation of most APC substrates by 26S
proteasome requires formation of ubiquitin chains, prevention of the ubiquitin chain
elongation alone may suffice to stabilize APC substrates. However, little is known about
how natural inhibitors of E3 ligases function by direct modulation of the ubiquitin transfer
process.
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The primary inhibitor of APC through interphase is early mitotic inhibitor 1 (Emi1), which
is required for accumulation of mitotic cyclins during S and G2 phase8. The C-terminal 150
amino acid fragment of Emi1 confers its inhibitory activity toward APC9, 10. This C-
terminal fragment of Emi1 contains destruction box (D-box), zinc-binding region
(ZBR) 10and its extreme C-terminal tail11, which interact with APC separately. Based on
competitive binding assays, it was proposed that Emi1 acts as a pseudosubstrate inhibiting
substrates binding to the D-box receptor site on APC10. Considering the total concentration
of the more than 100 APC substrates12, it is hard to explain how the Emi1 could possess
high enough affinity to occlude the E3-substrate interaction. Moreover, in this model, once a
substrate is already bound to APC, Emi1 could do nothing to inhibit its ubiquitylation and
degradation. Other mechanisms must explain the efficient inhibition of APC by Emi1. A
recent study suggested that Emi2, a meiotic analog of Emi1, may affect the ubiquitin
transfer from E2 to substrates13. However, solid kinetic evidence is still needed to further
support that argument for either protein.
Using a set of quantitative assays we dissected the inhibitory mechanism of Emi1. Emi1 acts
principally to block ubiquitin chain elongation by inhibiting ubiquitin transfer and
interrupting E2-E3 association.
Results
Emi1 competes for substrate binding and blocks ubiquitin chain extension
The presence of multiple sites on Emi1 for interacting with APC indicates that APC, Emi1
and substrate could form a ternary complex. Accordingly, we found that Emi1 bound both
APC and its substrate simultaneously (Supplementary Fig. S1). To ask how Emi1 regulates
APC activity, we simplified the reaction products by assays with a single-lysine securin
mutant (K48 SEC), Emi1 decreased the rate of conversion of the substrate to ubiquitin
adducts, consistent with its ability to compete with the substrate for APC binding (Fig. 1a).
Emi1 also significantly reduced the rate of ubiquitin chain assembly, as reflected in reduced
processivity (Fig. 1a). A decrease in processivity cannot be explained by competitive
inhibition of substrate binding. This indicates that Emi1 might interfere with the
ubiquitylation process also by preventing ubiquitin chain extension.
We examined the effects of Emi1 on the degradation of WT securin in a purified system
reconstituted with proteasomes (Fig. 1b). Ubiquitylation was still efficient (though
somewhat slower) in the presence of Emi1. By contrast, degradation was strongly inhibited
(Fig. 1b). When ubiquitylation was restricted to multiple-monoubiquitylations with
methylated ubiquitin, the degradation of securin was inhibited (Supplementary Fig. S2).
Furthermore, the proteolysis of securin in HeLa cell extracts was also inhibited by Emi1 by
either supplementing the extracts with lysine-free ubiquitin or methylated ubiquitin (Fig.
1c). In summary, Emi1 more strongly inhibits degradation than ubiquitylation, by
preferentially preventing ubiquitin chain elongation.
The features of UBCH10 and Ube2S, revealed in single encounter assays
Because Emi1 inhibits APC activity at two levels, it is hard to attribute its effects cleanly to
each process by traditional assays. To circumvent this problem, we set up a quantitative
single encounter reaction based on a recent SCF study14. As depicted in Fig. 2a, an “APC-
Sub” mixture and an “E2-Ub” mixture are pre-incubated separately to allow substrates to
pre-bind to APC in one reaction and E2 to be charged with ubiquitin in the other. When the
two are mixed, the radiolabeled substrate pre-bound to APC starts to acquire ubiquitins until
it dissociates from APC. Rebinding of the radiolabeled substrate to APC is prevented by the
excess of cold substrate. Hence the labeled reaction records the ubiquitylation profile from a
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single APC-substrate binding event. With this assay, we found that with methylated
ubiquitin UBCH10-catalyzed multiple monoubiquitylation was very processive, meaning
that UBCH10 rapidly transfers ubiquitins to several lysine residues on substrates (Fig. 2b
left part). The processivity was only slightly increased with WT ubiquitin (Fig. 2b right
part), indicating that UBCH10-catalyzed ubiquitin chain elongation is a slow process.
However, processivity increased greatly upon addition of Ube2S, consistent with previous
studies suggesting that Ube2S rapidly catalyzes ubiquitin chain assembly3, 15. The properties
of these two E2s were confirmed by a single encounter assay with the single-lysine securin
(Fig. 2c).
The domains of Emi1 responsible for inhibiting association of substrates with APC
To assess the effectiveness of Emi1 as a pseudosubstrate, we measured its ability to inhibit
the association of securin to APC (Fig. 3a). Both cold securin and Emi1 competitively
reduced the binding of labeled substrate to APC, as reflected in the decreased substrate
conversion rates, with cold securin slightly more potent (Fig. 3b). This suggests that though
Emi1 competes with substrates for APC binding, the effect is weak; its activity is no better
than that of a good substrate. To identify the domains of Emi1 responsible for this weak
competitive binding, we mutated known APC interaction domains9-11. Mutation of D-box
(DBM), zinc binding region (ZBRM), or deletion of the C-terminal tail (ΔCT), all reduced
the competitive ability of Emi1 (Supplementary Fig. S3a). When a 25 fold excess (1 μM) of
Emi1 mutants were pre-incubated with “APC-Sub” mixture (Fig. 3c), The DBM and ΔCT
could not compete for substrate binding even at this saturating concentration. In contrast,
ZBRM still retained some potency for substrate competition. These data imply that the C-
terminal tail is indispensable for recruitment and position of Emi1 to the catalytic site of
APC, whereas the ZBR may help orient Emi1 for optimal interaction with the D-box
receptor.
Despite weak competitive binding as a pseudosubstrate, Emi1 efficiently inhibits ubiquitin
chain elongation
Since competitive inhibition at the substrate binding site cannot explain the strong inhibition
exerted by Emi1 on substrate degradation, we tested if it has its major effect on ubiquitin
chain assembly. We used single-lysine securin in single encounter reactions with a full
complement of UBCH10, Ube2S and WT ubiquitin. As noted above, both Emi1 and securin
competed with substrates for APC binding, reducing the substrate conversion rate (Fig. 3d).
However, Emi1, but not securin, significantly reduced the processivity of ubiquitin chain
elongation, confirming that Emi1 is not simply a competitive inhibitor, but has an effect on
the process of ubiquitylation.
Ubiquitin chain elongation, but not multiple monoubiquitylation by UBCH10, is subject to
the effective inhibition by Emi1 via the ZBR domain
Among the three mutants, only deletion of the C-terminal tail had an obvious effect in
abrogating the inhibition of chain assembly primarily catalyzed by Ube2S (Fig. 3e). This
result alone implies that suppression of chain elongation by Emi1 involves a mechanism
different from the pseudosubstrate model.
To separate the role of Emi1 as an inhibitor of ubiquitin elongation from its role as
pseudosubstrate, we pre-incubated Emi1 variants with “E2-Ub” mixture before starting the
reaction (Fig. 4a). In this setting, Emi1 does not compete with radiolabeled substrate for
binding to APC. Thus, if Emi1 confers any inhibitory effect on ubiquitylation, it should be
entirely due to its effect on the process of ubiquitin transfer. Using this approach, we first
addressed how Emi1 inhibits ubiquitylation of WT securin by UBCH10 (without Ube2S).
Whereas the processivity contributed by multiple monoubiquitylation was only slightly
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reduced (Fig. 4b left), the processivity contributed by chain extension was greatly reduced
upon addition of Emi1 (Fig. 4b right), indicating that the chain extension by UBCH10 is
preferentially inhibited. This specific effect of Emi1 on UBCH10 activity was also
confirmed when single-lysine securin was used (Fig. 4d left panel). Moreover, titration
assays with Emi1 at various concentrations (Supplementary Fig. S3d and Fig. S3e) further
reinforced the conclusion Emi1 more effectively inhibits UBCH10 catalyzed chain
formation.
How does Emi1 distinguish between these two steps of ubiquitylation catalyzed by the same
E2? Based on the observations above that UBCH10 catalyzes rapid monoubiquitylation but
is relatively slow to elongate the chains, we hypothesized that the ubiquitylation with a low
reaction rate is more sensitive to Emi1 inhibition. If so, slowing down the rate of
monoubiquitylation should render it susceptible to Emi1 activity. UBCH5, an E2 previously
reported to support APC activity in vitro2, catalyzes multiple monoubiquitylation at a slower
rate than UbcH10 (Supplementary Fig. S3b). It turned out that both the processivity of
multiple monoubiquitylation of WT securin (Fig. 4c) and the rate of monoubiquitylation of
K48 securin (Fig. 4d right panel) by UBCH5 were significantly reduced by Emi1. This
supports the conclusion that Emi1 specifically targets the slow process of ubiquitylations
catalyzed by UBCH10 or UBCH5.
To ask which domain inhibits the slow process of ubiquitin transfer, we examined several
mutants. Previous study indicated that the zinc binding region (ZBR) antagonizes APC E3
ligase activity10. Using both WT securin (Fig. 4e and 4f) and single-lysine securin (Fig. 4d),
we found that ZBR mutant (ZBRM) failed to inhibit these ubiquitylations: ubiquitin chain
assembly by UBCH10 or monoubiquitylation by UBCH5. This indicates that the primary
role of ZBR is to inhibit ubiquitylation of APC substrates. Interestingly, C-terminal tail
deficient mutant also failed to inhibit the ubiquitylation by either UBCH10 or UBCH5 (Fig.
4d, 4e and 4f). This may suggest that the C-terminal tail of Emi1 positions the ZBR,
allowing it to interfere with ubiquitin transfer to substrates.
Rapid chain elongation by Ube2S is competitively inhibited by the C-terminal tail of Emi1,
which blocks its association with APC
To study the regulation of Ube2S by Emi1 on assembling ubiquitin chains, we again used
the single-lysine securin (K48 SEC) to simplify analysis of the products. Pre-incubation of
Emi1 in “E2-Ub” containing UbcH10 and Ube2S in the single encounter assay greatly
reduced this processivity (Fig. 5a). Since Ube2S mediates chain assembly at very high rate,
and we showed above that ZBR only efficiently inhibits the slow process of ubiquitylation,
we posited that this inhibition of Ube2S activity is not attributed to ZBR function. To prove
this, we employed a chimeric protein (Ub-L-securin) with ubiquitin fused to the N-terminus
of securin. Ube2S catalyzed very processive chain formation on Ub-L-securin without
initiation by UBCH10 (Fig. 5c). As shown in Fig. 5c, WT Emi1 profoundly reduced the
processivity of the reaction, and the two ZBR mutants (C401S and C401SC406S) retained
the full inhibitory activity against chain assembly, indicating that ZBR has very little effect
on Ube2S activity. To address the additional mechanism accounting for inhibiting Ube2S
activity, single encounter assays with K48 SEC were performed at various levels of Ube2S,
and the processivity contributed by Ube2S was calculated (Supplementary Fig. S4). Emi1
did not affect the Vmax, but significantly increased the Km of the reaction, indicating that
Emi1 acts as competitive inhibitor for antagonizing Ube2S activity. To define exact domains
responsible for this inhibitory activity, various Emi1 mutants were tested by the single
encounter assay with K48 SEC (Fig. 5b and 5d). Interestingly, all the variants with
mutations of the C-terminal tail (ΔCT, ΔCTΔZBR, ZBR and LR-AA) lost inhibitory activity,
whereas those with intact C-terminal tail (ZBRM, DBM and ZBR-CT) efficiently inhibited
Ube2S-catalyzed chain elongation, suggesting that the C-terminal tail of Emi1 alone may be
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sufficient to suppress Ube2S activity. Consistently, the C-terminal tail deficient mutant
(ΔCT) totally lost the inhibitory activity against chain formation upon Ub-L-securin by
Ube2S (Fig. 5c). Furthermore, the C-terminal tail peptide (residues 428-447) effectively
prevented ubiquitin chain elongation (Fig. 5e). The C-terminal tails of Ube2S and Emi1 are
very similar, especially in the last 4 amino acid (Fig. 5g). Ubiquitylation by Ube2S without
its C-terminal tail is not processive in the single encounter assay (Fig. 5f), suggesting the C-
terminal tail is required for Ube2S activity, consistent with a previous report3. Thus, we
concluded that Emi1 antagonizes the activity of Ube2S by competitively preventing the
association of this E2 to APC via the C-terminal tail.
The C-terminal tails of both Emi1 and Ube2S associate with the cullin subunit of APC by
electrostatic interactions
Consistent with kinetic assays, Ube2S associated with the APC complex and deletion of the
C-terminal tail abolished this interaction (Fig. 6a and Supplementary Fig. S5a). These results
suggest that the C-terminal tail may be the only domain on Ube2S responsible for APC
binding with high affinity. By comparison, the Emi1 mutant without the C-terminal tail still
associated with APC complex (Supplementary Fig. S5b). Moreover, the binding of Ube2S to
APC was not dependent on Cdh1 (Fig. 6a), suggesting that some APC core subunit directly
associates with this E2. The C-terminal tail is very rich in basic residues (Fig. 5g), implying
this E2-E3 association may be driven by electrostatic force. Protein-protein association
through electrostatic interactions is sensitive to salt, which blocks the attraction between
opposite charges. High salt washing disrupted the APC-Ube2S binding (Fig. 6b), consistent
with a previous study3.
It has been noted that the processive ubiquitylation catalyzed by SCF necessitates the
electrostatic interactions between the cullin subunit of SCF and the C-terminal tail of its
cognate E2, cdc3416. We guessed that Ube2S may act in a similar fashion. Both Emi1 (Fig.
6c and Supplementary Fig. S5c) and Ube2S (Fig. 6e) directly associate with APC2.
Moreover, the interaction between APC2 and Ube2S or Emi1 is abolished either by washing
with high salt buffer, or by deletion of their C-terminal tails (Fig. 6d and 6e). These results
suggest that Emi1 interferes with the activity of Ube2S mainly through disrupting the
dynamic electrostatic association between the E2's C-terminal tail and APC2.
To evaluate contributions of these domains to Emi1 function in a more complex system
approximating the cell and in particular containing the complete degradation machinery, we
compared the inhibitory activity of Emi1 mutants on securin degradation in highly
concentrated HeLa cell extracts (Fig. 7a). In extracts the D-box mutant (DBM) of Emi1 at
relatively high concentration (2 μM) efficiently inhibited the degradation of securin,
suggesting that Emi1 must have a role, other than as pseudosubstrate. In contrast, mutation
of either ZBR or C-terminal tail, the two domains responsible for suppressing chain
elongation, largely abolished the inhibitory activity against protein degradation. Thus, we
concluded that Emi1 inhibits the degradation of APC substrate primarily through
suppression of ubiquitin chain elongation.
Deubiquitylation activity enhances the inhibitory effect of Emi1
Studies in cell extracts were qualitatively similar to those in the purified system that we
presented here. However, there was a notable difference. Multiple-monoubiquitylated
substrates were easily detected in the reconstituted but purified degradation reactions (Fig.
1b and Supplementary Fig. S2), but ubiquitylated substrates were barely detectable in cell
extracts that were inhibited by Emi1 (Fig. 1c). This difference suggests that the non-
degradable ubiquitylated proteins were converted back to their basal states by
deubiquitylating enzymes (DUBs) in cell extracts. In a complete kinetic scheme, DUBs
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could play a kinetic proofreading role in distinguishing substrates and determining a precise
order of degradation5. Therefore, we tested in a reconstituted system whether DUBs
synergized with Emi1 in blocking degradation. USP2 catalytic domain can efficiently
remove monoubiquitin from APC substrate (Supplementary Fig. S6). As shown in Fig. 7b,
addition of USP2 alone had little effect on substrate degradation. Under these conditions
Emi1 at relatively low concentration only partially stabilized the substrate. However,
addition of both the DUB and Emi1 showed much greater inhibition, strongly indicating that
DUBs can enhance the effect of Emi1 on stabilizing APC substrates.
Discussion
These studies support a model in which Emi1 is a multipurpose inhibitor of APC (Fig. 8). In
the absence of Emi1, a substrate is recruited to APC by binding to the D-box co-receptor
formed by Cdh1 and APC1017, the concerted activities of UBCH10 and Ube2S enable APC
to rapidly polyubiquitylate the substrate (Fig. 8a). When Emi1 is expressed, the D-box of
Emi1 can compete with substrates for binding to the D-box receptor (Fig. 8b). When the D-
box receptor is occupied by a substrate, the ZBR domain of Emi1 allows the initial
monoubiquitylation of the substrate, but strongly inhibits chain formation by UBCH10;
meanwhile, the C-terminal tail of Emi1 also antagonizes Ube2S activity by competitively
preventing its binding to APC2. By its combinatorial action Emi1 effectively inhibits
ubiquitin chain extension. Products without ubiquitin chains cannot easily be degraded by
the proteasome, and are reverted by DUBs to their original state.
Reconsideration of the standard model of Emi1 activity as a pseudosubstrate
Currently, it is thought that inhibitors of APC, such as Emi1, Acm1 and BubR1 act as
pseudosubstrates10, 18, 19. Effective blockage of substrate binding to APC requires a very
high affinity interaction between Emi1 and the substrate binding site. Our competition
assays show that Emi1 is not a particularly good competitor. To support the pseudosubstrate
model, it was shown previously that cyclin B poorly competes for Emi1 binding to the
APC10. Indeed, based on our finding, addition of saturating amount of cyclin B would lead
to the formation of cyclin B-APC-Emi1 complex, rather than competitive dissociation. The
function of Emi1 as a pseudosubstrate only partially explains its inhibitory effect.
The key function of the C-terminal tail of Emi1 in its inhibitory activity
Our data strongly suggest that the C-terminal tail of Emi1 plays a pivotal role in various
aspects of Emi1 activity: First, The tail facilitates recruiting Emi1 to the catalytic site of
APC, for optimal binding to the D-box receptor; second, it positions ZBR to inhibit
ubiquitin transfer; third, it competitively blocks the binding of Ube2S to APC. Moreover,
the electrostatic interaction with APC2 could provide very high kon, enabling Emi1 to
interfere with APC activity at any point of the ubiquitylation process.
The effect of DUBs on Emi1 inhibitory activity
DUBs have been proposed to confer greater selectivity on substrate selection. Distributive
substrates, which cannot obtain sufficient ubiquitins during a single E3-substrate encounter
are converted by DUBs to basal status5. Thus, they cannot be degraded until processive
substrates are first degraded, freeing APC. By this means, Emi1 theoretically transforms all
APC substrates into distributive substrates. Furthermore, it was recently shown that many
DUBs have preference for monoubiquitylated substrates but are inefficient in removing
ubiquitin chains20. Therefore, DUBs are more effective in acting on ubiquitylated substrates,
when chain elongation is prevented by Emi1, explaining how DUBs can magnify the
inhibitory effect of Emi1.
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In summary, this study provides the first kinetic evidence showing that natural inhibitors of
E3 ligase exert their effects by direct interference with E2 activity. We also show that,
paired with the activities of DUBs, suppression of the 2nd step of ubiquitylation (chain
elongation) alone is sufficient to stabilize E3 substrates. These mechanistic features may
provide new ways to think about therapeutic targets affecting critical E3 ligases in various
diseases.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Emi1 stabilizes substrates by preventing ubiquitin chain assembly.
(a) 200 nM 33P labeled single-lysine securin (K48 SEC) was ubiquitylated by 4 nM
APCCdh1 in the presence (+) or absence (-) of 200 nM Emi1. The reactions were
supplemented with UBCH10, Ube2S and WT ubiquitin, and analyzed by autoradiography.
(b) Ubiquitylation and degradation of WT securin was examined in the presence or absence
of Emi1. 100 nM 33P labeled WT securin, 4 nM purified APCCdh1, 100 nM Emi1 and 8 nM
26S proteasomes were used in the reconstituted reaction, supplemented with UBCH10,
Ube2S and WT ubiquitin and analyzed by autoradiography. In the graphs the remaining
substrates were quantified and plotted as percentages of input radiolabeled securin at
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indicated time points. These data are representative of three independent experiments. (c)
Degradation of 35S labeled WT securin was examined in cell extracts prepared from HeLa
S3 cells synchronized at G1 phase. WT ubiquitin (WT Ub), lysine-free ubiquitin (Ub-K0),
methylated ubiquitin (Me-Ub) or Emi1 were added as indicated and analyzed by
autoradiography. The amount of remaining securin was quantified and plotted at indicated
time points. These data are representative of three independent experiments.
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Figure 2.
A single encounter assay for APC catalyzed ubiquitylation by UBCH10 and Ube2S.
(a) As shown in this design diagram, In the “APC-Sub” mixture, 20 nM APCCdh1 and 40
nM 33P radiolabeled securin were pre-incubated; in the “E2-Ub” mixture, E1, E2, ubiquitin,
energy regenerating cocktail and 40 μM unlabeled substrate were pre-incubated. The
reaction was started by combining the two mixtures, quenched with SDS sample buffer, and
analyzed by autoradiography. As a negative control, 40 μM unlabeled substrate was added
to “APC-Sub” complex to measure its efficacy for competing for APC binding. (b) Single
encounter assay was performed to test the ubiquitylation of WT securin. Methylated
ubiquitin (Me-Ub) or WT ubiquitin (WT-Ub), Ube2S and UBCH10 were supplemented as
indicated. (c) Single encounter assay was performed to test the ubiquitin chain assembly on
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the single-lysine securin (K48 SEC). WT ubiquitin was used in this assay. UBCH10 and
Ube2S were added as indicated. These reactions were analyzed by autoradiography.
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Figure 3.
Single encounter assays to study the competition of Emi1 for substrate binding to APC.
(a) Experimental design to test the relative competitiveness of securin and Emi1 variants on
ubiquitylation. (b) 100 nM cold securin or Emi1 was pre-incubated with APCCdh1 and 33P
radiolabeled WT securin in the single encounter reaction. (c) 1μM Emi1 and its variants
were pre-incubated with “APC-WT SEC” In the single encounter reaction and ubiquitylation
was assayed. In both (b) and (c), methylated ubiquitin (Me-Ub) was used to restrict the
reactions to multiple monoubiquitylation. (d) 50 nM cold securin or WT Emi1 was pre-
incubated with APCCdh1 and radiolabeled single-lysine securin (K48 SEC) in the single
encounter assay supplemented with Ube2S. (e) Emi1 variants were pre-incubated with
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“APC-K48 SEC” mixture in the single encounter assay involving Ube2S. Effectiveness of
Emi1 variants as inhibitors was measured and compared. In (d) and (e), WT ubiquitin (WT-
Ub) was used to support ubiquitin chain assembly. All the reactions above were analyzed by
autoradiography, and substrate conversion rate and processivity was calculated. * indicates
nonspecific band.
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Figure 4.
Emi1 inhibits the slow process of ubiquitin transfer from charged UBCH10 or UBCH5.
(a) Assay was designed for testing how Emi1 affects ubiquitin transfer from charged E2.
Emi1 variants were pre-incubated with “E2-Ub” mixture in the single encounter assay to
study the possible function of Emi1 against E2 activity. (b) 2 μM Emi1 was pre-incubated
with “E2-Ub” to test how Emi1 affects the ubiquitylation of 33P radiolabeled WT securin
catalyzed by 1μM UBCH10. Methylated ubiquitin (Me-Ub) was used to measure the
processivity of multiple-monoubiquitylation; Wild type ubiquitin (WT-Ub) was used to
measure the processivity from both monoubiquitylation and chain extension. The
processivity of reactions was calculated, and the mean value ± s.d. of five independent
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experiments is shown. Note that the processivity contributed by chain extension in control
and Emi1 (+) group is 1.01 (4.11-3.1) and 0.25 (2.9-2.65) respectively. (c) 2 μM Emi1 was
pre-incubated with “E2-methylated Ub” to test how Emi1 affects the ubiquitylation of 33P
radiolabeled WT securin catalyzed by 1 μM UBCH5. (d) Emi1 variants were pre-incubated
with “E2-WT Ub” to evaluate their effects on ubiquitylation of the single-lysine securin
(K48 SEC) by either UBCH10 or UBCH5. The reaction products by UBCH10 with di-
ubiquitin and products by UBCH5 with mono-ubiquitin were quantified respectively. (e)
Emi1 variants were pre-incubated with “UBCH10-WT Ub” to examine their inhibitory
activities on the polyubiquitylation of WT securin. (f) Emi1 variants were pre-incubated
with “UBCH5-methylated Ub” to study their inhibitory activities on multiple
monoubiquitylation of WT securin. All the reactions above were analyzed by
autoradiography. * indicates nonspecific band.
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Figure 5.
The C-terminal tail of Emi1 suppresses Ube2S activity by competitively blocking the
interaction between Ube2S and APC
a) 2 μM Emi1 was pre-incubated with “E2-WT Ub” mixture in the single encounter assay.
1μM UBCH10 and 1μM Ube2S were supplemented to fully support ubiquitin chain
assembly on the single-lysine securin (K48 SEC). (b) Emi1 variants were pre-incubated with
“E2-WT Ub” mixture in the single encounter assay to evaluate their effects on ubiquitin
chain assembly on the single-lysine securin (K48 SEC). UBCH10 and Ube2S were added in
this assay. The processivity of reactions was quantified. (c) Inhibitory activity of Emi1
variants on ubiquitylation of Ub-L-securin was examined. Ub-L-securin is a chimeric
protein with ubiquitin fused to the N-terminus of WT securin. Emi1 variants were pre-
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incubated with “E2-WT Ub” mixture in the single encounter reaction supplemented only
with Ube2S. The processivity of reactions was quantified. (d) Schematic representation of
Emi1 mutants in the C terminal APC inhibitory domain (residues 300-447). The amino acid
positions of destruction box (DB), zinc binding region (ZBR) and C-terminal tail (CT) were
shown. (e) 10 μM Emi1 C-terminal tail peptide (CT peptide) (residues 428-447) was pre-
incubated either with “APC-K48 SEC” or with “E2-WT Ub” mixture in the single encounter
assay. The effects of the peptide and the Emi1 protein on Ube2S activity were compared. 10
μM 3X FLAG peptide (23 aa) was used as control peptide. (f) WT Ube2S or Ube2S
deficient in the C-terminal tail (ΔCT) was applied in the single encounter assay with single-
lysine securin (K48 SEC). (g) The C-terminal tails of human Emi1 and Ube2S were aligned
with ClustalX. Basic residues are marked with pink color. These reactions above were
analyzed by autoradiography. * indicates nonspecific band.
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Figure 6.
The C-terminal tail of Emi1 and Ube2S associate with APC2 through electrostatic
interaction.
(a) His tagged WT Ube2S or Ube2S without C-terminal tail (ΔCT) was incubated with
purified APC complex and recombinant Cdh1 as indicated. Mixtures were subjected to a
His-tag pull-down assay, followed by western blot for respective proteins. (b) His tagged
Ube2S was incubated with purified APC complex, followed by His-tag pull-down with Ni-
NTA beads. The beads were then washed with high salt buffer (with 300 mM NaCl) or low
salt buffer (with 5 mM NaCl) before they were subjected to Western blot for APC2, APC8
and Ube2S. (c) GST tagged Emi1 or GST was incubated with APC2 expressed in rabbit
reticulocyte lysates and subjected to a GST pull-down, followed by a Western blot with anti
APC2 antibody. (d) GST, GST tagged Emi1 or GST tagged Emi1 without C-terminal tail
(ΔCT) was incubated with APC2 expressed in rabbit reticulocytes respectively, subjected to
GST pull-down, washed with high salt buffer (with 300 mM NaCl) or low salt buffer (with 5
mM NaCl) as indicated, and analyzed by Western blot for APC2. (e) His tagged Ube2S or
His tagged Ube2S without C-terminal tail (ΔCT) was incubated with APC2, subjected to
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His-tag pull-down, washed with low salt (5 mM NaCl) or high salt (300 mM NaCl) buffer,
and analyzed by western blot for APC2 and Ube2S. The competition of Emi1 with Ube2S
for binding to APC2 was also tested. Uncropped images are presented in Supplementary Fig.
S7.
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Figure 7.
The inhibitory activity of Emi1 against securin degradation in the presence of
deubiquitylating enzymes.
(a) Degradation of 400 nM WT securin was performed in cell extracts prepared from HeLa
S3 cells synchronized at G1 phase. 2 μM Emi1 variants were supplemented as indicated.
Samples were analyzed by Western Blot for securin. In the graphs the remaining substrates
were quantified and plotted as percentages of input securin at indicated time points. These
data are representative of three independent experiments. Uncropped images are presented
in Supplementary Fig. S7. (b) Ubiquitylation and degradation of 100 nM 33P labeled WT
securin was examined in a reconstituted assay in the presence of 4 nM APCCdh1 and 8 nM
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26S proteasome. WT ubiquitin, UBCH10 and Ube2S were added in the reactions. The
deubiquitylating enzyme (DUB), USP2 catalytic domain, and Emi1 were supplemented as
indicated. Emi1 at relatively low concentration was added to the reaction, ensuring that the
degradation of securin was only partially inhibited, in order to evaluate the impact of DUB
on Emi1 inhibitory activity. These reactions were analyzed by autoradiography. The amount
of remaining substrates at indicated time points was calculated, and plotted as percentages of
input radiolabeled securin. These data are representative of three independent experiments.
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Figure 8. Model for inhibition of APC by Emi1
(a) In the absence of Emi1, the processive multiple monoubiquitylation by UBCH10 and
processive ubiquitin chain elongation by Ube2S enable the substrate to be rapidly
polyubiquitylated by APC and targeted for degradation by 26S proteasome.
(b) Emi1 inhibits the degradation of APC substrates at multiple levels. The C-terminal tail
enables Emi1 to closely approach APC catalytic site through electrostatic interaction. The
D-box of Emi1 competitively blocks access of substrates to the D-box co-receptor formed
by APC10 and Cdh1. When a substrate is bound to APC, the activity of ZBR of Emi1
permits the rapid multiple monoubiquitylation of the substrate, but suppresses the slow
ubiquitin chain elongation catalyzed by UBCH10. Meanwhile, the C-terminal tail of Emi1
inhibits the processive ubiquitin chain assembly by Ube2S through competitively occluding
its binding to APC2. As a result, APC substrates without sufficient ubiquitin chains cannot
be efficiently degraded by proteasome, and are converted to their original status by
deubiquitylating enzymes (DUBs).
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